Ypsomed Holding AG
Company Profile
Business description
Ypsomed, based in Burgdorf, Switzerland, develops and manufactures self-injection devices like pens, autoinjectors, and infusion systems for global pharma and biotech companies. The company shifted focus to business-to-business injection systems, divesting its diabetes care segment to supply device platforms to pharma partners.The company operates in a market driven by strong growth in biologics, biosimilars, patient self-administration, and GLP-1 therapies for obesity. To meet demand, Ypsomed has embarked on an ambitious capacity expansion program, with capital expenditure reaching approximately 50% of sales in recent years. This investment is partially derisked through customer co-financing, which aligns incentives and secures future volume commitments before launch.
Contact
Brunnmattstrasse 6
Burgdorf3401
CHET: +41 344244111
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 March 2027
Employees
2,099
Stocks News & Analysis
stocks
5 star fully franked ASX dividend payer
stocks
An undervalued stock to buy that even Warren Buffett likes
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,886.60 | 35.90 | 0.41% |
| CAC 40 | 8,072.42 | 6.06 | -0.08% |
| DAX 40 | 25,517.46 | 143.04 | 0.56% |
| Dow JONES (US) | 51,481.51 | 347.11 | -0.67% |
| FTSE 100 | 10,680.20 | 4.68 | -0.04% |
| HKSE | 24,523.57 | 118.94 | -0.48% |
| NASDAQ | 26,820.38 | 248.34 | -0.92% |
| Nikkei 225 | 65,481.27 | 396.35 | -0.60% |
| NZX 50 Index | 13,683.63 | 147.05 | -1.06% |
| S&P 500 | 7,683.69 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,709.30 | 29.60 | 0.34% |
| SSE Composite Index | 3,830.45 | 6.83 | 0.18% |